Pfizer (PFE)
$28.05
0.35 (1.26%)
PFE Stock Quote Delayed 30 Minutes
What Should Apple Do With Its Cash?
Apple's cash on hand figure of $245 billion gives the company a variety of options, but one possibility stands out among the rest.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 â FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report â FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out â FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why â FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
157.27B
PE Ratio
-561.00
EPS
-0.05
Volume (Avg. Vol.)
17.27M
Day's Range
$27.67 - $28.09
52-Week Range
$25.20 - $37.80
Dividend & Yield
$1.64 (5.85%)
PFE Stock Predictions, Articles, and Pfizer News
3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
3 Big Stock Charts for Friday: Merck, Broadcom and Advanced Micro Devices
Three stocks -- AMD, MRK and AVGO -- are going to end the week with their charts in pivotal positions. Here's what to watch.
All Signals Are Positive for Buying Abbott Laboratories
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group
Stock charts of FISV, PFE and PNC are run through the technical trading wringer, and come out as your top prospects.
InvestorPlace Roundup: The Top Stocks in the Market Today, Including CGC Stock
InvestorPlace's financial journalists, analysts and advisors discuss the top stocks and the worst, shining a light on what to buy and sell.
7 Dow Jones Stocks Set to Charge Higher
The following 7 Dow Jones stocks trade at attractive levels and will play leadership roles as their respective industries continue to advance.
Should You Buy PFE Stock on Pfizer’s Joint Venture With Glaxo?
A mutual fund stock has many unrelated businesses without the separation of a mutual fund. PFE stock is moving away from this designation.
Bristol-Myers Squibb Stock Is Coming Back Slow, but That’s Fine
Bristol-Myers Squibb stock took a hit in October. The stock is still rebounding, albeit slowly which makes it a good value.
GlaxoSmithKline (GSK) Stock Pops on Pfizer Joint Venture
GlaxoSmithKline (GSK) stock is up today on news of a new joint venture with Pfizer (PFE) for a consumer healthcare business.
PFE Stock Has Broken Its Slump and Could Challenge Former Highs
A new generation of drugs as well as several other factors could Pfizer could drive PFE stock to all-time highs.
7 Stocks to Buy to Survive a Bear Market
These seven stocks are resisting widespread market volatility and will help investors with surviving a bear market. Here's what you need to know about each.
Monday’s Vital Data: Pfizer, Goldman Sachs and Caterpillar
Options trading was buzzing in Pfizer, Goldman Sachs and Caterpillar on Friday. Here are the metrics that matter moving forward.
Pfizer Stock Has Multiple Positive Catalysts
Pfizer stock could be boosted by the company's rising investments and strong pipeline. PFE stock would be attractive on a major drop.
This Health Care Stock Could Pay Off Big
Today I am recommending a bullish trade on AstraZeneca PLC (NYSE:AZN), a biopharmaceutical company focused on the development, discovery and commercialization of prescription medicines for a variety of diseases.
Biogen Stock Rebounds After Impressive Q3 Earnings
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
